After two volatile years, FDA approvals in 2024 settled closer to their 10-year average. Will nominated commissioner Marty Makary shake things up, or maintain a steady ship?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Senior, M. Nat. Biotechnol. 42, 355–361 (2024).
Senior, M. Nat. Biotechnol. 41, 174–182 (2023).
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V. & Pelidou, S. H. Biomedicines 7, 97 (2019).
Schmidt, M. E. et al. Neuropsychopharmacology 49, 1437–1447 (2024).
Shiga, T. Eur. Heart J. Suppl. 24, D11–D21 (2022). (Suppl. D).
Senior, M. Nat. Biotechnol. 42, 362–366 (2024).
Senior, M. Nat. Biotechnol. 42, 1331–1338 (2024).
Senior, M. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02506-7 (2024).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Senior, M. Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next?. Nat Biotechnol 43, 159–165 (2025). https://doi.org/10.1038/s41587-025-02555-6
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02555-6
